Financings

Allon Therapeutics Inc. raised $10.1 million in a private placement of stock and warrants.

DARA Biosciences Inc. raised $10.3 million through a public offering of preferred stock and warrants.

iTeos Therapeutics SA raised $3.9 million in a Series A round for cancer immunomodulators.

Pacira Pharmaceuticals Inc. secured a $27.5 million debt financing facility through Oxford Finance.

Raptor Pharmaceutical Corp. set up a $40 million at-the-market deal with Cowen and Co. LLC.

Supernus Pharmaceuticals Inc. raised $50 million in its initial public offering.

Deals

Abbott paid $110 million to acquire kidney drug AP214 from Action Pharma A/S.

AnaptysBio Inc. is partnering with Gilead Sciences Inc. to develop antibody therapeutics.

Axerion Therapeutics Inc. entered an Alzheimer's research deal with AstraZeneca plc.

Caisson Biotech LLC licensed its heparosan-based drug delivery platform to Novo Nordisk A/S.

EUSA Pharma Ltd. is being acquired by Jazz Pharmaceuticals Inc. for $700 million cash.

Tolero Pharmaceuticals Inc. licensed Btk drugs from MannKind Corp. for $130 million.

. . . And More

See BioWorld Today for coverage of the American Academy of Neurology annual meeting and the New York Biotechnology Association annual meeting.

Actelion Ltd.'s macitentan hit the endpoint in a Phase III trial for pulmonary arterial hypertension.

Amgen Inc. got a complete response letter for Xgeva (denosumab) in the prevention of bone metastases.

Johnson & Johnson, of New Brunswick, N.J., won FDA approval of Levaquin (levofloxacin) for plague.

Novartis AG won FDA approval of Afinitor (everolimus) for tuberous sclerosis complex-related non-cancerous kidney tumors.

Protalix BioTherapeutics Inc. and Pfizer Inc. got FDA approval of Elelyso (taliglucerase alfa) in Gaucher.

Targacept Inc.'s partnership with AstraZeneca plc on TC-5214 was terminated.

Vivus Inc.'s erectile dysfunction drug Stendra (avanafil) gained FDA approval.